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Ampullary adenoma is rare, but it is increasingly being 
recognized due to the widespread use of endoscopy and 
cross-sectional imaging. It is a premalignant neoplasm that 
is managed by resection. Traditionally, it is managed by 
surgical resection by either pancreaticoduodenectomy or 
transduodenal ampullectomy, both of which are associated 
with significant morbidity and mortality. For these reasons, 
endoscopic papillectomy (EP) has been explored as an 
alternative to surgical resection because it avoids surgical 
morbidity and is relatively safe (complication rate of 18.2%, 
mortality rate <0.5%);1 however, the blind spot of EP is the 
intraductal extension of the adenoma into either the bile 
duct or the pancreatic duct. 
Endoscopic retrograde cholangiopancreatography 
(ERCP)-guided intraductal radiofrequency ablation (ID-
RFA) has been proposed as an attractive and effective 
endobiliary ablative therapy because of its ease of delivery, 
controlled application of thermal energy, low cost, and 
acceptable safety.2,3 In this issue of Gut and Liver, Choi et 
al.4 assessed the efficacy and safety of ERCP-guided ID-
RFA for the treatment of residual intraductal lesions of 
ampullary adenoma, which is a critical limitation of EP. 
They used a 7 F temperature-controlled catheter (ELRA; 
STARmed, Goyang, Korea) with a dedicated generator. A 
clinical ID-RFA pilot study was performed on 10 patients 
with residual intraductal adenoma (eight patients with 
low-grade dysplasia and two patients with high-grade dys-
plasia). The median diameter of the intraductal adenomas 
was 9 mm (range, 5–10 mm) in the common bile duct 
(CBD) and 5 mm (range, 4–11 mm) in the pancreatic duct. 
The technical success rate was 100%, and no severe adverse 
events were reported. Only two patients (20%) had mild 
post-procedure pancreatitis, and one (10%) had an asymp-
tomatic biliary stricture. Over a median follow-up period 
of 253 days, nine patients showed no residual or recurrent 
adenomatous lesions after ID-RFA. 
To date, the therapeutic efficacy of ERCP-guided ID-
RFA has been evaluated for unresectable malignant biliary 
obstruction,2,3 bridge to surgery,5 and residual adenoma 
in the CBD after EP.6,7 To reduce the complications of the 
conventional ID-RFA systems (Habib, Boston Scientific, 
Marlborough, MA, USA), a temperature-controlled ra-
diofrequency (RF) catheter (ELRA) has been developed. 
It automatically adjusts the temperature of the RF cath-
eter tip so that it does not exceed a preset temperature to 
prevent tissue overheating. This ELRA RFA system was 
used to confirm safety and usefulness of ID-RFA through 
preclinical animal experiments and clinical studies.3,8,9 Al-
though theoretically, ID-RFA is expected to be an effective 
local treatment for malignant biliary obstruction, there are 
still many controversies concerning its benefits in terms 
of stent patency and survival. The effectiveness of RFA 
has been demonstrated in a recent large-scale random-
ized controlled trial. Gao et al.10 compared the efficacy and 
safety between the RFA+ stent group and the stent-only 
group in patients with unresectable malignant biliary ob-
struction, such as those with cholangiocarcinoma and am-
pullary cancer; 174 participants were randomly assigned in 
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a 1:1 ratio and completed the two scheduled ERCPs with 
an interval of approximately 3 months. The median overall 
survival was significantly higher in the RFA group (14.3 
months vs 9.2 months; hazard ratio [HR], 0.49; 95% confi-
dence interval [CI], 0.35 to 0.68; p<0.001). In the subgroup 
analysis of cholangiocarcinoma, survival benefit was also 
demonstrated (13.3 months vs 9.2 months; HR, 0.55; 95% 
CI, 0.39 to 0.77; p<0.001). As such, recent research results 
emphasize the positive therapeutic effect of RFA. 
Notably, this study provides the potential of using RFA 
for the eradication of residual adenoma after EP. Although 
it is subject to the limitations of retrospective and small-
sized endoscopic research, we could find several other in-
teresting discussion points on ID-RFA. First, to the best of 
our knowledge, this study is the first to investigate temper-
ature-controlled ID-RFA for intraductal residual adenoma 
after EP. Although the ID-RFA setting was different from 
the established ID-RFA setting for malignant biliary ob-
struction (mid to distal CBD 7–10 W, 80°C, 2 minutes), the 
authors presented a relatively safe ID-RFA setting for in-
traductal residual adenoma (median RFA time, 65 second; 
range, 45 to 90 seconds for CBD). In particular, the Habib 
RF catheter has a long RF ablation zone of approximately 
25 mm in length, which may lead to higher rates of stric-
ture development and an increased risk of severe adverse 
events. On the other hand, the ELRA 7 W 11 mm RFA 
catheter is short in length and can reduce the occurrence of 
severe adverse events and biliary strictures because it can 
minimize damage to the normal duct. Second, the safety of 
ID-RFA within or at the pancreatic orifice is of great con-
cern, particularly in the absence of exophytic disease. But 
this study suggests a relatively safe ID-RFA setting (7 W: 
median RFA time, 30 seconds; range, 45 to 90 seconds for 
pancreatic duct [PD]) for eradication of pancreatic ductal 
adenomatous extension. Since there are few reports on 
pancreatic ID-RFA, it might be a safe way that pancreatic 
ID-RFA followed by the PD stent placement.
This study was retrospective in nature and aimed to 
evaluate the safety and adjunctive therapeutic role of intra-
ductal RFA after incomplete EP. Given that the alternative 
to endoscopic management, that is pancreaticoduode-
nectomy, is not satisfactory, the opportunity to provide 
patients with a novel endoscopic alternative to ID-RFA 
is very attractive. In conclusion, endobiliary ID-RFA is a 
promising treatment option for residual/recurrent intra-
ductal adenoma after EP. Additional controlled studies 
will be helpful in determining the optimal RFA dosimetry 
(power, target temperature and duration), clinical benefits, 
medico-economic validity of ID-RFA, and follow-up strat-
egies after EP. 
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